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Abstract:
Over diagnosis is the inevitable flip side of early detection resulting in unnecessary labelling of well women with a diagnosis of cancer and possible unnecessary treatment.
Over diagnosis occurs because breast cancers have different rates of growth and slow growing cancers are preferentially detected by screening. Some of these slow growing screen-detected cancers may never have been clinically apparent during an individual's lifetime. Evaluating the benefits and risks of screening are complex but this has been performed for the UK population by an independent review led by Professor Marmot. It might be possible to limit over diagnosis by Identifying women with "low risk disease" earlier either at the point of screening when additional investigations could be delayed (possibly for ever) so that they are not subjected to additional diagnostic tests, or at the point of diagnosis. Both these options would require major re-education of clinicians and the public who would need to accept that screening is 'deliberately ignoring a cancer' There is a long surgical history of reducing the burden of treatment which continues today with trials of management of the axilla and reducing or even omitting radiotherapy for low risk disease. The Low Risk Ductal Carcinoma in situ trial (LORIS) has started to Identify a group of breast cancer patients who could avoid surgery and be offered active monitoring. We need to consider planning a similar trial for row risk invasive breast cancer. My responses alterations are detailed below 1 EDITOR'S COMMENTS:
MGWallis
1.1 If you could please just check the refs and language that would be great.
These have both been amended as requested.
There are a number of places 'word' has suggested simplification but in most cases I think this loses the sense of the statement.
1.2
Personally I would leave the figures as they are; I think the visual impact is much better than the written word; if you wish to shorten the text instead then fine -if not then I'm happy either way. I will leave to your discretion.
I have left the figures and their captions alone and I have not substantially altered the main text. I am happy to do this but I am within word limit and when teaching trainees (and colleagues) I find that they have difficulty with these concepts so repetition is no bad thing. When I read papers I find it really helpful if the main text and the figures each 'stand-alone' provided it is not just repetition 2 EDITORIAL OFFICE REQUIREMENTS:
Please add your Figure Legend Over diagnosis occurs because breast cancers have different rates of growth and slow growing cancers are preferentially detected by screening. Some of these slow growing screen-detected cancers may never have been clinically apparent during an individual's lifetime. Evaluating the benefits and risks of screening are complex but this has been performed for the UK population by an independent review led by Professor Marmot. It might be possible to limit over diagnosis by Identifying women with "low risk disease" earlier either at the point of screening when additional investigations could be delayed (possibly for ever) so that they are not subjected to additional diagnostic tests, or at the point of diagnosis. Both these options would require major re-education of clinicians and the public who would need to accept that screening is 'deliberately ignoring a cancer'
There is a long surgical history of reducing the burden of treatment which continues today with trials of management of the axilla and reducing or even omitting radiotherapy for low risk disease. The Low Risk Ductal Carcinoma in situ trial (LORIS) has started to Identify a group of breast cancer patients who could avoid surgery and be offered active monitoring. We need to consider planning a similar trial for row risk invasive breast cancer.
Over diagnosis: disease detected that, in the absence of screening, would not otherwise have 1 become clinically apparent and would not have had any adverse consequences on the individual. 2 This is a highly charged political issue to the extent that the BMJ now runs an annual international 3 conference. (1) Dr Margaret McCarthy a Scottish General Practitioner and lead writer for the BMJ 4 summarised the issue in 2007. 'Too much testing of well people and not enough care for the sick 5 worsens health inequalities and drains professionalism, harming both those who need treatment 6 and those who don't. (2) 7 Screening for breast cancer continues to be mired in debate. The benefit in terms of mortality 8 reduction seems to have been settled (3-5) even if its magnitude and who to screen is less clear. The 9 over diagnosis debate summed up in 2009 by Gilbert Welsh (6) "the question is no longer whether it 10 occurs but how often it occurs" has not been resolved by the 'independent reviews' summarised by 11 Houssami (7) and there are continuing contradictory new publications (8, 9) . 12
Why does over diagnosis occur at screening? 13
Breast cancer is not one disease with a uniform growth rate ( Figure 1 ). Screening finds both fast and 14 slow growing cancers. The periodic nature of screening means that the faster growing cancers (those 15 with a worse prognosis that are likely to progress to metastatic disease) are less likely to be found at 16 screening and have a greater tendency to appear between screens (interval cancers). The lower 17 grade and slower growing cancers are much more likely to be picked up by screening; length bias. 18 (figure 2) (10). These cancers are more likely to be over diagnosed because the preclinical, screen-19 detected cancer is progressive but the person dies prematurely of another cause before the time at 20 which symptoms would have occurred or the growth rate of a truly progressive cancer is not rapid 21 enough to give rise to symptoms during the person's life time. It is also possible that a cancer stops 22 growing and becomes indolent for some reason or possibly even regresses (11) but this is, to say the 23 least, controversial (12). Additionally, the slower growing cancers tend to produce more of a stromal 24 reaction so they are easier to perceive on mammography (13) The paradox for the clinician providing breast screening is that detecting 'early' breast cancer leads 26 to mortality reduction so they are encouraged and incentivised to find more 'early' cancers even if 27 some of these might never have become clinically apparent or trouble the patient so over diagnosis 28 and early detection are the two sides of the same coin. 29
The difficulty for individual treating clinicians and patients is that for any one individual patient we 30 cannot readily distinguish who has been 'saved' by screening and early treatment and who has been 31 harmed by unnecessary labelling with a lifelong diagnosis, unnecessary treatment and its side effects 32 (figure 3). So, we are left with Gray and Raffle's popularity paradox. "The greater the harm through 33 over diagnosis and overtreatment from screening, the more people there are who believe they owe 34 their health, or even their life, to the programme." (14) 35
Quantifying both the benefits of screening in terms of reducing mortality from breast cancer and the 36 risk of over diagnosis is complex and over many years the discussion has become polarised with 37 quoted rates of over diagnosis between 1 and 2% (15) and 52% (16). The UK government responded 38 to public pressure in October 2013 and jointly commissioned an independent review with Cancer 39
Research UK. This review was performed by a panel of independent experts who had never 40 previously published about breast screening and was chaired by Prof MG Marmot (4). 41
In theory, the debate should be relatively simple to resolve using the randomised controlled trials. 42
The excess of cancers diagnosed into the intervention arm (screening) should be balanced by the 43 excess of cancers in the control group after the trial has finished. The problem is that in real-life this 44 has never happened as screening does not stop. So, the magnitude of the effect must be 45 "calculated" by a variety of epidemiological and statistical tools using observational data, historical 46 data and geographical controls. As the effect on mortality seems to continue long after the trial has 47 ended (17) each estimate has to must decide how long to wait for the excess cancers to be balanced 48 out. The shorter the period (18) the larger the estimate of over diagnosis and the longer the period 49 of surveillance the smaller the estimate (19).
It is beyond the scope of this article to consider in any detail the statistical and epidemiological 51 complexities behind the calculations particularly as this was performed in great detail by the 52 Marmot Review (4). 53
Estimating the benefits of screening: 54
How good are the estimates of benefits? Ignoring the statistical confidence in the actual numbers, 55 all the randomised controlled trials are old and treatment has improved so their relevance to 56 'today's practice' is debated. There are well rehearsed arguments about the randomisation 57 methodology and imperfections and disagreements about what outcome should be measured. The 58 trials were initially designed and powered to measure breast cancer specific mortality but this can be 59 biased by how accurately the cause of death is recorded and how/if this was validated. Reductions in 60 overall mortality are very small and depend on length of follow up. Finally, how is the risk reduction 61 presented? Should the benefit be expressed in terms of the whole population (clearly important to 62 any potential funders of screening), namely the benefit of sending the invitation or should the 63 benefit be expressed in terms of actually attending the screening appointment which is higher (5). 64 This is a figure that is of more use to the individual woman concerned about balancing the harms 65 and benefits of attending her appointment. 66
Estimating over diagnosis 67
The complexity of estimating the degree of over diagnosis is even harder. Carter (20) identified four 68 types of study: follow-up of randomised controlled trials, pathology and imaging follow up, 69 modelling and epidemiological cohort studies. He concluded that the need for a well-designed 70 ecological and cohort studies in multiple settings, underpinned by internationally agreed standards 71 and unbiased researchers. De Gelder (21) describes seven separate methodologies: these including 72 inclusion or exclusion of DCIS, using the screening age range or the woman's lifetime and finally 73 whether the rate of over diagnosis is related to the women invited, the women screened or even the Once a relative risk has been "agreed" then this needs to be translated to the individual screening 76 programme and the population it serves. This will vary because of the interval between screens and 77 the intrinsic risk of a population being offered screening. The specific risk groups selected, age and 78 personal family history being the most obvious, but in some populations as well as opportunistic 79 programmes background density is being used to select specific women for additional imaging (22). 80
Finally screening performance is dependent on the test(s) being used and the professionals 81 implementing and interpreting them. 82
The balance of harm and benefit. 83
Having taken all these issues into account the Marmot review (4) came up with a set of figures 84 specifically related to the United Kingdom based on their meta-analysis of 11 randomised controlled 85 trials with 13 years of follow-up. They estimated a 20% (11 to 20%) reduction in breast cancer 86 mortality for women invited to screening over a 20-year period. By applying this reduction to the 87 National Breast Screening Programme in the United Kingdom they estimated that one breast cancer 88 death would be prevented for every 235 women invited to screening and that 180 women would 89 need to be screened to prevent one breast cancer death. The panel acknowledged that there is 90 uncertainty around these numbers and concluded that the estimates of benefits would be in the 91 range of one breast cancer death prevented for approximately 250 women invited. In 2013 at the 92 time of the report they considered that that corresponded two approximately 1300 deaths from 93 breast cancer being prevented each year or 22,000 years of life saved. They balanced this against 94 the risk of over diagnosis which they estimated to be at approximately 19% of the cancers diagnosed 95 based on a 20-year programme. 96
This translated into notional figures for 10,000 women invited to screening from the age of 54 over a 97
20-year period. Estimating that 681 breast cancers (invasive and DCIS) will be diagnosed, 129 of 98 these will represent over diagnosis and 43 deaths from breast cancer will be prevented. 99 and risk is complex (23). There is a need to provide this information in an understandable form. Fig 4  101 (24) is one of the many pictograms available from the UK. Hersch (25) developed a similar tool and 102 tested the effects in an Australian population. At telephone interview 3 weeks after the intervention 103 more women receiving the tool felt able to make an informed choice when compared to the control 104 group. The intervention also improved knowledge about screening and breast cancer risk. However, 105 it did lead to a reduction in positive attitudes to breast screening and a reduction in the number of 106 women intending to attend screening over the next 2 to 3 years. Longer follow up and impact on 107 attendance is awaited. (25) 108 The consequences of over diagnosis are the psychosocial effect of being labelled with a diagnosis of 109 breast cancer (26) and the burden of unnecessary treatment. The problem is that we cannot 110 currently distinguish which of these 681 individual women diagnosed with screen detected breast 111 cancer will be lucky enough to be one of the 43 whose death from breast cancer has been prevented 112 and which are the 129 who have been overtreated as neither group dies from cancer. As we have 113 very little data on the natural history of untreated breast cancer it is a major challenge to use 114 historical data, based on women having received conventional treatment, to separate these two 115 groups into the ones who are cured and the ones who did not require treatment in the first place. 116
This leaves three potential approaches, 117
Reducing over diagnosis by 118  Identifying women with "low risk disease" earlier either at the point of screening when 119 additional investigations could be delayed (possibly for ever) so that they are not subjected 120 to additional diagnostic tests, labelled with a diagnosis of cancer and offered treatment. The principle group at risk of over diagnosis is the older woman. The older the age at detection the 128 more likely she is to have a cancer diagnosis that would either not present or not cause problems 129 within her life. AgeX, a nationwide cluster randomization of extending the NHS Breast Screening 130 Programme began as a trial of additional screening at ages 47-49 and at ages 71-73, now has ethical 131 approval to continue triennial invitations at ages 71-76 or at ages 71-79 thereby assessing the effects 132 of continuing triennial screening for several years after age 70 (27). 133
Using radiological features to predict risk is not foreign to radiology with well recognised guidelines 134 for the management of incidental nodules identified at CT scanning (28). Tabar has documented the 135 common mammographic features associated with high grade invasive cancers (29) and Alexander 136 with low grade invasive cancers (30) but using this to reduce the number of recalls or identifying 137 cancers not to investigate has never been part of the screening programme culture mainly because 138 our current technology and knowledge is not good enough to perform this task with enough 139 specificity or certainty. This dilemma is best illustrated by the problem of microcalcification. The 140 majority of calcification that we biopsy turns out to be benign and the more we identify and biopsy 141 the larger number of 'incidental' pathological risk or low risk malignant lesions are found (31) 142 however this should be balanced against the fact that a few of these lesions contain small high grade 143
invasive disease (the cancers we really need to pick up). High rates of DCIS detection are associated 144
with higher rates of small high-grade invasive cancer detection (32,33) and lower interval cancer 145 rates (31) 146 risk with potential support from functional imaging which preferentially images metabolically active 150 disease (37), the whole ethos and purpose of screening would need to be changed. 151
Radiologists and screen readers are performance monitored by their cancer detection rates (38) and 152
haunted by their missed cancers if not hunted through the legal system with fears of missing a 153 diagnosis and of litigation being a major cause of both over investigation and thus over diagnosis 154 (39) 155 With the exception of tomosynthesis, which can reduce recall as well as increasing cancer detection 156 (40) new technology for screening or supplemental screening for higher risk women is always 157 introduced to find more cancer (41). Unfortunately, early publications do not have long enough 158 follow up to report interval cancers and do not usually make any effort to distinguished high risk 159 from low risk disease. Reporting more small cancers and fewer node positive cancers (probably 160 those most likely to be over diagnosed) is not a proper substitute for reporting grade and biological 161 marker characteristics. 162
Patient expectation and knowledge will need a radical overhaul as we will need to explain that 163 screening is not about finding cancer but about finding killing cancer which means that in the very 164 extreme scenario an abnormality is identified either by the film reader or machine reader that looks 165 like a low risk cancer and it is just ignored and allowed to grow on the principle 'that what you don't 166 know about can't harm you'. Alternatively, the woman is recalled to explain that she probably does 167 have a cancer but its' not an 'important one' so we do not intend to confirm this by biopsy or other 168 imaging, which might throw up another 'false positive' lesion, we are just going to recommend 169 active monitoring. At least in this case the woman can make an informed choice. 170 progressive reduction in the aggressiveness of surgical treatment of breast cancer. Fisher showed 174 that, after 25 years of follow up, radical mastectomy offered the same survival as simple 175 mastectomy (42). He further showed in NSABP -06 that, at 20 years, local surgery with radiotherapy 176 was equivalent to mastectomy, for invasive cancer less than 4 cm in size (43). In more recent years 177 the recommendations for the amount of normal breast tissue surrounding a cancer (surgical margin) 178 has steadily reduced (44). 179
Management of the axilla has similarly changed. Removal of all axillary nodes via axillary lymph node 180 dissection (ALND) was considered to be standard treatment (45) but is associated with significant 181 morbidity (46). It was replaced by Sentinel Lymph Node Biopsy (SLNB) (47,48) and then in 2011 the 182 ACOSOG Z001115 trial (49) showed that in a specific group of women with a low burden of axillary 183 disease identified at sentinel lymph node sampling they do not gain any additional benefit from 184 proceeding to therapeutic axillary node clearance. Although there is still controversy regarding the 185 results and other trials are currently in progress (50) of treatments to deliver the same dose from 5 weeks to 3 weeks and more recently 1 week reduces 195 side effects without effecting outcomes however the results of accelerated partial breast 196 radiotherapy are less clear cut. (57). Given that current local recurrence rates are so low the most marker to standard clinical features, ER PR and HER2 to identify women at very low risk of local 199 recurrence who will receive a recommendation to omit radiotherapy (55) 200 Identifying a group of breast cancer patients who could avoid surgery and be offered active 201 monitoring 202 DCIS has been described as a disease of screening (18), as it classically present as mammographic 203 calcifications rather than a mass lesion and it is considered to be a non-obligate precursor of 204 invasive cancer with an unknown course of progression. When treated it has a very low breast 205 cancer specific mortality (57). The addition of radiotherapy after local surgery reduces local 206 recurrence rates (58), particularly in women with close margins (59). Of those women who have 207 subsequent events nearly half are invasive and there is some evidence that death from breast cancer 208 although rare is usually/always preceded by an invasive event (57). The challenge is to identify those 209 women with DCIS who are unlikely to recur or alternatively find a marker which can predict 210 recurrence at diagnosis or predict recurrence before it becomes a risk for death. More recent 211 prognostic scores to determine who will benefit from radiotherapy require validation if they are to 212 gain widespread acceptability. (60) 213 Histopathology currently divides DCIS into three grades on morphological grounds and there is good 214 evidence that low-grade disease recurs late (61) and more frequently as low grade invasive cancer 215 (62-64) and that if a higher grade invasive disease occurs it is likely to be a new primary. This is 216 supported by Sagara using the SEER database (65) who showed no significant survival benefit of 217 breast surgery for low-grade DCIS with a 10-year overall survival of 91% in the non-surgery group 218 and 87.9% in the surgery group and 10-year breast cancer specific survival of 93.4% in the non-219 surgery group and 98.8% in the surgery group. These trials have not been simple to set up, like ProtecT (73) before it, they have been slow to 243 recruit in the initial stages as the medical profession need to change ingrained behaviour of offering 244 surgery and patients have been brought up to expect "cancer" to be removed. (77) It is difficult to 245 sell the concept that active monitoring is about avoiding treatment until it is necessary and that 246 treatment at that point can be offered when cure can still be offered. Providing safety nets for both impossible or making follow-up so intrusive that the primary surgery would have been preferable. 249
Securing a solid diagnosis at presentation prior to randomisation relies on biopsy techniques that 250 provide adequate material to reduce the risk of missing something serious (in the case of 251 microcalcification high grade or invasive disease). Each trial has a different strategy to reduces this 252 risk, all requiring vacuum assisted biopsy but LORIS, the UK trial, has added central pathology review 253 so that at least there is consistency in the diagnosis of "low risk" disease. The hardest paradox is the 254 presence of extensive calcification where on one hand there is professional anxiety about missing 255 high grade DCIS or an invasive cancer somewhere in the area of concern verses the fact that the 256 patient concerned has the "most to lose" in terms of the conventional extensive surgical options 257 including mastectomy. 258
Active monitoring is equally hard to balance as there is no good evidence about how these lesions 259 change over time, presumably they will grow but this is not necessarily a predictor of progression to 260 invasion, so a balance must be drawn between continuous monitoring verses regular intervention 261 with further biopsies. All trials have defined criteria for intervention to reduce the chances that 262 active monitoring by mammography does not turn into active monitoring by vacuum assisted biopsy. 263
As the three trials will provide a cohort of women managed without surgery Cancer Research UK and 264
Dutch Cancer Society has funded a joint project preventing unnecessary breast cancer treatment 265 PRECISION (78) to trying to identify imaging, biological and genetic markers for risk of recurrence 266 from a series of historical treated cohorts that will then be prospectively validated in the new trials. 267
Having committed to no surgical trials for DCIS the next step is to consider future trials for 'low risk' 268 invasive cancer. We have good follow up data suggesting conventional treatment of tubular cancers 269 is associated with an excellent prognosis. In Rakha's series of 102 cases all distant recurrences 270 followed on from the development of a second higher grade cancer (79). We also know that local 271 recurrence rates are now very low (55) and adding proliferation markers to conventional markers Page 12 of 18 could well increase confidence. Just leaving these cancers to active monitoring is one choice. 273
Minimally invasive image guided percutaneous ablation is still in its infancy but there are multiple 274 small trials, with a wide range of tumour sizes, suggesting high rates of technical success with low 275 complication rates but only 75% 'complete ablation'. (80). We must of course resist the temptation 276 to replace relatively simple low risk surgery with expensive high technology imaging because we can. 277
What do we need to do to prepare for this brave new world? 278
Firstly, we need to be open and honest about the screening programme and start to change the 279 pervasive publicity around cancer. Personalised medicine is not just about more more more, the 280 new wonder drug and magic bullet it is also about cancer not being one disease, it's a rainbow. We 281 do have new treatments for the red end but there are lots of cancers at the blue end that don't need 282 treating in a hurry, under artificial politically driven waiting time targets, and might need less or even 283 no treatment at all. This is not a new covert way of saving money for social care. 284
Secondly, we need to ensure that every one of our patients has the opportunity to be involved in a 285 trial, as the late Professor Adele Francis was very fond of telling her surgical colleagues 'it's not good 286 enough to just keep on doing what we have always done' 287 Finally, we need to optimise the enormous data base that is NBSS, link it to cancer registry and all 288 the digital images stored on PACS and if necessary start storing the 'raw' not for processing data, 289 which is needed for machine learning. Then start using the information to design the trials of the 290 future to maximise benefit and minimise harm. 
